CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0209 (clinicaltrials.gov NCT No: NCT01849874)
Title:The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Principal Investigator:Robert Coleman
Treatment Agent:Liposomal Doxorubicin; MEK162; Paclitaxel; Topotecan
Study Status:Open
Study Description:The goal of the main part of this clinical research study is to learn if MEK162
can help to control cancers of the ovary, fallopian tube, or primary
peritoneum. In this study, MEK162 will be compared to 3 other chemotherapy
drugs. The safety of MEK162 and the other drugs will also be studied.

The goal of the screening part of this study is to learn if you are eligible to
take part in the main study.

Hide details for General InformationGeneral Information

Disease Group:Fallopian Tube; Ovary; Peritoneum
Phase of Study:Phase III
Treatment Agents:Liposomal Doxorubicin
MEK162
Paclitaxel
Topotecan
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Array BioPharma Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults